Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9ULT0
UPID:
TTC7A_HUMAN
Alternative names:
-
Alternative UPACC:
Q9ULT0; Q2T9J9; Q6PIX4; Q8ND67; Q9BUS3
Background:
Tetratricopeptide repeat protein 7A plays a pivotal role in cellular processes by ensuring the localization of phosphatidylinositol 4-kinase to the plasma membrane. This action is crucial for the synthesis of phosphatidylinositol 4-phosphate, a key lipid signaling molecule.
Therapeutic significance:
The protein's involvement in gastrointestinal defects and immunodeficiency syndrome 1 highlights its potential as a target for therapeutic intervention. Understanding the role of Tetratricopeptide repeat protein 7A could open doors to potential therapeutic strategies.